Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.53 |
| ▸ | CA9 | Q16790 | 8/20 | 0.53 |
| ▸ | CA1 | P00915 | 8/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | S100A4 | P26447 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31028807 | 1.00 | CA2 (0.53) | CA2CA9CA1MEN1NPC1 | |
| SCHEMBL5199553 | 0.83 | CA2 (0.53) | CA2CA9CA1MEN1NPC1 | |
| SCHEMBL31028813 | 0.83 | CA2 (0.53) | CA2CA9CA1MEN1NPC1 | |
| SCHEMBL13261334 | 0.75 | CA2 (0.53) | CA2CA9CA1MEN1NPC1 | |
| SCHEMBL922607 | 0.75 | CA9 (0.58) | CA2CA9CA1MEN1NPC1 | |
| SCHEMBL7130484 | 0.75 | CA2 (0.42) | CA2CA9CA1MEN1NPC1 | |
| SCHEMBL7610058 | 0.75 | CA2 (0.53) | CA2CA9CA1MEN1NPC1 | |
| SCHEMBL10371873 | 0.75 | CA2 (0.53) | CA2CA9CA1MEN1NPC1 | |
| SCHEMBL7148444 | 0.75 | CA9 (0.53) | CA2CA9CA1MEN1NPC1 | |
| SCHEMBL1371709 | 0.75 | CA2 (0.53) | CA2CA9CA1MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025136671-A1 | ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-4540230-A1 | ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | Ensem Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023244710-A1 | ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-6555555-B1 | Inhibitors of interleukin-6 and/or interleukin-12; for example 4,5-dimethyl-1,1-dioxidebenzo(b)thiophene; treating various inflammatory diseases, autoimmune diseases, cancer, osteoporosis | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-04-29 | — | — | US | disclosed |
| US-20030073706-A1 | Fused thiophone derivatives and drugs containing the same as the active ingredient | KONISHI MIKIO (JP) | 2003-04-17 | — | — | US | disclosed |
| US-6420391-B1 | PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-1067128-A1 | FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073706-A1 | Fused thiophone derivatives and drugs containing the same as the active ingredient | TPMT, CD47, THPO | CA2 3155/4885CA9 3056/4885CA1 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.